Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Kansas Board of Regents

Status: Completed

Conditions: Autosomal Dominant Polycystic Kidney Disease

Treatments: Other: Water prescription

Study type: Interventional

Funder types: Other

Identifiers

NCT00759369

11451

Details and patient eligibility

About

Autosomal dominant polycystic kidney disease (ADPKD) is the most common single gene disorder that is potentially fatal. ADPKD is caused by mutations in either of two genes (PKD1, PKD2). Cysts begin to develop primarily in renal collecting tubules in utero and continue to form and expand throughout the patient's life. One of the goals of the study is to formulate a water prescription for use in clinical trials to determine the effect of sustained water diuresis on the progression of ADPKD.

Full description

The proposed study will devise a quantitative model to estimate the amount of water an individual would need to ingest in order to lower the 24 h mean urine osmolality to a level below plasma (~285 mOsm/Kg). This osmolality goal is chosen because the 24h median urine osmolality of humans is ordinarily ~753 mOsm/Kg, much greater than 285 mosm/Kg (6, 7). In other words, normal humans are usually anti-diuretic during waking hours and while asleep. Median 24h urine volume is ~1225 ml (range 1051 - 2270). In temperate climates the insensible losses of water in sweat, respiration and stool are nearly balanced by the water ingested in solid and semi-solid foods and derived from metabolism. Thus, daily urine volume measured upon arising in the morning is a reasonably good indicator of the volume of fluids drunk over the preceding 24 h.

Enrollment: 11 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ADPKD verified by ultrasound, CT or MRI, family history or physical exam
• Normal creatinine clearance, calculated by Cockroft-Gault formulat
• Good general health
• Controlled blood pressure, < 140/90
• Absence of urinary tract symptoms such as dysuria, hesitancy, diminished flow

Exclusion criteria

• Azotemia
• Uncontrolled hypertension
• Urinary tract symptoms, dysuria, hesitancy, diminished flow, gross hematuria
• Diabetes mellitus, cancer, hematologic disorder
• Unable to follow directions
• Solitary kidney
• History of CHF, liver dysfunction or hyponatremia
• Currently taking diuretics
• Nephrotic range proteinuria (3.5 g/day)

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

11 participants in 1 patient group

1

Experimental group

Description:

Water prescription

Treatment:

Other: Water prescription